Ventavis

Treatment for Pulmonary Hypertension

CoTherix, Inc. Announces Filing of Ventavis NDA

Click here for more information on Ventavis

SOUTH SAN FRANCISCO, Calif., July 01, 2004 -- CoTherix, Inc. announced today that the Company submitted yesterday its new drug application (NDA) to the United States Food and Drug Administration seeking approval to market Ventavis (iloprost solution for inhalation) as a therapy for the treatment of pulmonary arterial hypertension.

Ventavis is currently marketed in various European countries by Schering AG, Germany. CoTherix licensed the exclusive U.S. rights to Ventavis from Schering AG in October 2003.

About CoTherix, Inc.
CoTherix, Inc. is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the treatment of cardiopulmonary and other chronic diseases. CoTherix's lead product candidate, Ventavis, is an inhaled formulation of iloprost, a prostacyclin analog. The Company is developing Ventavis for the treatment of pulmonary arterial hypertension, a highly debilitating disease characterized by severe constriction of the blood vessels of the lungs.
For more information, please visit www.cotherix.com.

Posted: July 2004

Related Articles

Ventavis (iloprost) FDA Approval History

View comments

Hide
(web2)